AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 17578315
Drug: Ampeptide elemente,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampeptide elemente, 0.4 g three times a day for two weeks, then adjusted to 0.2 g each time for a total of 1.8 g a day for two more weeks.
Trial: 15272511
Drug: 25% metronidazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% metronidazole gel (test)
Trial: 18069178
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel (control)
Trial: 11603386
Drug: Pre- and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre- and post-therapy with photopheresis
Trial: 8081786
Drug: Intravenous OKT3
RxNorm normalized name: Humanized OKT3
DrugBank: Teplizumab (DB06606)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous OKT3 for seven days
Trial: 25564143
Drug: Simvastatin 20
RxNorm normalized name: simvastatin 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 20 mg once daily for 4 days
Trial: 21485673
Drug: Intravenous paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous paracetamol
Trial: 26467455
Drug: Bisphosphonate treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bisphosphonate treatment
Trial: 17488771
Drug: Trimetazidine (TMZ)
RxNorm normalized name: trimetazidine
DrugBank: Trimetazidine (DB09069)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimetazidine (TMZ) 60 mg acute loading dose prior to PCI
Trial: 15487709
Drug: Cross‐linked hylan
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cross‐linked hylan G‐F 20
Trial: 9631345
Drug: Expectancy ratings
RxNorm normalized name: Aratinga erythrogenys feather extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Expectancy ratings during therapy
Trial: 14998068
Drug: Sumatriptan 100
RxNorm normalized name: sumatriptan 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan 100 mg
Trial: 28501812
Drug: Culturally adapted
RxNorm normalized name: casein, emmental cultured
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Culturally adapted physiotherapy assessment and treatment
Trial: 24142616
Drug: methylprednisolone aceponate
RxNorm normalized name: Methylprednisolone aceponate
DrugBank: Methylprednisolone aceponate (DB14643)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: methylprednisolone aceponate 0.1% based cream
Trial: 21598242
Drug: Sequential docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential docetaxel followed by carboplatin (sDC)
Trial: 21945310
Drug: Combination docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination docetaxel and carboplatin (cDC)
Trial: 19099676
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (ICS) - beclomethasone dipropionate 200 microg/d
Trial: 19099676
Drug: Oral montelukast
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral montelukast 5 mg, once at bedtime for 6 months
Trial: 3631471
Drug: nalbuphine 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: nalbuphine 5 mg
Trial: 1416128
Drug: naloxone 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: naloxone 0.2 mg
Trial: 27903341
Drug: Propofol group
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Propofol group (P group) - received sufentanil 0.1 μg/kg and propofol 1.5 mg/kg followed by a continuous infusion of 3-6 mg·kg-1·h-1 of propofol
Trial: 12716662
Drug: Unsaturated fatty
RxNorm normalized name: omega-3 polyunsaturated fatty acids
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsaturated fatty acids (O, T, L)
Trial: 10981217
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment modalities for acute dislocation of the patella; specific treatments not detailed
Trial: 10981217
Drug: Various treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Various treatment modalities for recurrent dislocation of the patella; specific treatments not detailed
Trial: 1435590
Drug: Praziquantel therapy
RxNorm normalized name: Praziquantel
DrugBank: Praziquantel (DB01058)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Praziquantel therapy at a daily dose of 25 mg/kg for 2 days
Trial: 6376718
Drug: Four-drug combination
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug combination chemotherapy program with CCNU
Trial: 6376718
Drug: Four-drug combination
RxNorm normalized name: Four-Way
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Four-drug combination chemotherapy program with mechlorethamine
Trial: 30202873
Drug: Split-virion inactivated
RxNorm normalized name: influenza, inactivated, split virus or surface antigen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Split-virion inactivated influenza vaccine
Trial: 17894651
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (intermediate exposure category)
Trial: 17894651
Drug: Aspirin (ASA)
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin (ASA) and non-steroidal anti-inflammatory drugs (NSAIDs) exposure (high exposure category)
Trial: 23025273
Drug: Horse meat
RxNorm normalized name: Horse meat specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Horse meat consumption (2 portions of 175 g/week)
Trial: 16802483
Drug: 1.5 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 ml/kg Hartmann's solution
Trial: 16802483
Drug: 15 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 ml/kg Hartmann's solution
Trial: 10371111
Drug: Simvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin (20 mg daily for 4 weeks)
Trial: 3519058
Drug: Guar gum
RxNorm normalized name: Guar Gum
DrugBank: Guar gum (DB13446)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Guar gum (20 g)
Trial: 28116761
Drug: Daily 1-hour
RxNorm normalized name: Deponit 0.2 MG/HR Daily Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily 1-hour nap opportunity
Trial: 21520194
Drug: Maintenance peginterferon
RxNorm normalized name: peginterferon alfa-2a Injection [Pegasys]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance peginterferon treatment
Trial: 12592052
Drug: Unoprostone isopropyl
RxNorm normalized name: Unoprostone Isopropyl
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unoprostone isopropyl 0.15% ophthalmic solution
Trial: 10971309
Drug: Dofetilide 1000
RxNorm normalized name: Dofetilide
DrugBank: Dofetilide (DB00204)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dofetilide 1000 microg, twice daily
Trial: 8982131
Drug: poly‐L‐lactic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: poly‐L‐lactic acid screws
Trial: 1443810
Drug: Intubated patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intubated patients (0.5 and 0.75 ml)
Trial: 24844333
Drug: Negative-pressure wound
RxNorm normalized name: Microcyn Negative-Pressure Wound
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Negative-pressure wound therapy (NPWT)
Trial: 25223209
Drug: Bromfenac 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromfenac 0.1% monotherapy (n = 23)
Trial: 11385810
Drug: Novolizer (MDPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novolizer (MDPI) at peak inhaled flow rates of 90 l/min
Trial: 11385810
Drug: Novolizer (MDPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novolizer (MDPI) at peak inhaled flow rates of 60 l/min
Trial: 11385810
Drug: Novolizer (MDPI)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novolizer (MDPI) at peak inhaled flow rates of 45 l/min
Trial: 11385810
Drug: Pulmicort Turbuhaler
RxNorm normalized name: Pulmicort Turbuhaler
DrugBank: Budesonide (DB01222)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pulmicort Turbuhaler at peak inhaled flow rate of 60 l/min
Trial: 2451954
Drug: 1040 regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1040 regimen (cisplatin 80 mg/m2, vincristine 1 mg, methotrexate 10 mg/m2 on days 1, 2, 3, and bleomycin 10 mg/m2 on days 1, 2, 3)
Trial: 29536284
Drug: Motivational Interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational Interviewing + Cognitive Behavioral Therapy (MI + CBT)
Trial: 26440643
Drug: 0 g
RxNorm normalized name: Co Q-10 Gummies
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0 g polydextrose/d (control)
Trial: 23980734
Drug: Resveratrol and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol and quercetin combination (RQ)
Trial: 18199920
Drug: Telmisartan 80
RxNorm normalized name: telmisartan 80 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Telmisartan 80 mg plus hydrochlorothiazide 25 mg
Trial: 18199920
Drug: Valsartan 160
RxNorm normalized name: valsartan 160 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Valsartan 160 mg plus hydrochlorothiazide 25 mg
Trial: 8815701
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with two nucleosides
Trial: 1475040
Drug: 1750 mg
RxNorm normalized name: vancomycin 1750 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1750 mg of the DA antagonist alpha‐methyl‐p‐tyrosine (AMPT)
Trial: 1475040
Drug: 0.65 g/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.65 g/kg ethanol
Trial: 27400469
Drug: Decoction of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Decoction of Nicotiana tabacum leaves mouthwash (10 mL 3 times a day for 5 days)
Trial: 27400469
Drug: Placebo mouthwash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthwash (10 mL 3 times a day for 5 days)
Trial: 17645577
Drug: L-T3 (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-T3 (50 microg qd) for 3 weeks
Trial: 8618852
Drug: Viral RNA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Viral RNA level < or = 100,000 copies/ml
Trial: 25187119
Drug: Zoledronate 5
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronate 5 mg (N=703)
Trial: 22045833
Drug: Continuous celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous celecoxib 200 mg/day
Trial: 22045833
Drug: Intermittent celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent celecoxib 200 mg/day
Trial: 2884081
Drug: Azelastine 4.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azelastine 4.4 mg
Trial: 28059603
Drug: Mastery Learning
RxNorm normalized name: Noxzema Clean
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mastery Learning (ML) BLS course
Trial: 25782427
Drug: Vitamin K1
RxNorm normalized name: vitamin K1
DrugBank: Phylloquinone (DB01022)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin K1 supplementation (1000 μm phylloquinone, one pearl softgel capsule daily for 4 weeks)
Trial: 25782427
Drug: Placebo (one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (one placebo capsule daily for 4 weeks)
Trial: 17660909
Drug: Early-loaded ITI
RxNorm normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early-loaded ITI implants (loaded 6 weeks after surgery)
Trial: 17660909
Drug: Conventionally-loaded ITI
RxNorm normalized name: Arthur Itis
DrugBank: Trolamine salicylate (DB11079)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Conventionally-loaded ITI implants (loaded 12 weeks after surgery)
Trial: 12227482
Drug: Oral finasteride
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral finasteride (1 mg per day)
Trial: 12227482
Drug: Topical 2%
RxNorm normalized name: menthol topical 2% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 2% minoxidil solution
Trial: 2644531
Drug: sequential methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: sequential methotrexate and fluorouracil followed by leucovorin
Trial: 29858517
Drug: Perineural injections
RxNorm normalized name: ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Perineural injections
Trial: 29858517
Drug: Intraneural injections
RxNorm normalized name: bleomycin
DrugBank: Bleomycin (DB00290)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraneural injections
Trial: 23666832
Drug: Directly observed
RxNorm normalized name: direct blue 2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Directly observed home-based daily iron therapy (DOHBIT)
Trial: 23666832
Drug: Unsupervised self-treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Unsupervised self-treatment at home
Trial: 22010015
Drug: Dulanermin 8
RxNorm normalized name: Dulanermin
DrugBank: Dulanermin (DB12349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulanermin 8 mg/kg for 5 days with paclitaxel and carboplatin (arm 2)
Trial: 22010015
Drug: Dulanermin 8
RxNorm normalized name: Dulanermin
DrugBank: Dulanermin (DB12349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulanermin 8 mg/kg for 5 days with paclitaxel, carboplatin, and bevacizumab (arm 4)
Trial: 22010015
Drug: Dulanermin 20
RxNorm normalized name: Dulanermin
DrugBank: Dulanermin (DB12349)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulanermin 20 mg/kg for 2 days with paclitaxel, carboplatin, and bevacizumab (arm 5)
Trial: 12844472
Drug: Vitamin-mineral drug
RxNorm normalized name: Mineral Oil
DrugBank: Mineral oil (DB11057)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin-mineral drug combination containing dimethylaminoethanol (DMAE)
Trial: 7890006
Drug: Gabexate mesilate
RxNorm normalized name: mesylate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gabexate mesilate (Gab) infusion after liver resection
Trial: 2778501
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg daily oral sobrerol for 7 days
Trial: 31084488
Drug: Triamcinolone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triamcinolone (40 mg) and lidocaine (1.5 mL) injection into the glenohumeral joint 8 weeks after surgery (group 1)
Trial: 31084488
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline injection (group 2)
Trial: 28218420
Drug: Aspirin and/or
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin and/or folic acid treatment
Trial: 19005755
Drug: Omeprazole, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, amoxicillin, metronidazole, and bismuth subcitrate (Group A)
Trial: 19005755
Drug: Omeprazole, amoxicillin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Omeprazole, amoxicillin, and clarithromycin (Group B)
Trial: 12199276
Drug: Pilocarpine (15-30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pilocarpine (15-30 mg/day)
Trial: 7656926
Drug: Thyroid replacement
RxNorm normalized name: Thyroid
DrugBank: Thyroid, porcine (DB09100)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thyroid replacement therapy (TRT)
Trial: 2486951
Drug: Nimesulide 100
RxNorm normalized name: nimesulide 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimesulide 100 mg every 12 hrs for 5 days
Trial: 31836203
Drug: Daily disposable
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily disposable soft contact lenses (Dailies Total 1, Dailies Aqua Comfort, TruEye, Biotrue Oneday)
Trial: 21110014
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole (RPZ) 20 mg
Trial: 21110014
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole (RPZ) 10 mg
Trial: 21110014
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole (RPZ) high-dose
Trial: 21110014
Drug: Rabeprazole (RPZ)
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Rabeprazole (RPZ) low-, middle-, and high-dose
Trial: 14564194
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of dialysis
Trial: 14564194
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of dialysis
Trial: 10027500
Drug: Slow-release nifedipine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Slow-release nifedipine (calcium channel blocker)
Trial: 27575450
Drug: 1.5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.5 mg/kg sugammadex
Trial: 24447651
Drug: 4 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 mg/kg sugammadex
Trial: 29465480
Drug: Trivalent influenza
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent influenza vaccine
Trial: 3307518
Drug: Ketorolac 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 1.5 mg/hour
Trial: 3307518
Drug: Ketorolac 3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketorolac 3.0 mg/hour
Trial: 14990633
Drug: Gefitinib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gefitinib (500 mg/d and 250 mg/d)
Trial: 24940526
Drug: Placebo therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo therapy
Trial: 7539182
Drug: Selective alpha
RxNorm normalized name: alpha tocopherol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective alpha 1 blockers
Trial: 19815265
Drug: Silodosin 8
RxNorm normalized name: silodosin 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin 8 mg once daily with breakfast (continuing treatment)
Trial: 19815265
Drug: Silodosin (de
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Silodosin (de novo treatment)
Trial: 4083300
Drug: 24-hour sustained-release
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 24-hour sustained-release theophylline formulation, Uniphyl
Trial: 4083300
Drug: Twice-daily compound,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice-daily compound, Theo-Dur
Trial: 25996838
Drug: HBvaxPRO® (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HBvaxPRO® (10 μg)
Trial: 16740846
Drug: Stimulant (dexamphetamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant (dexamphetamine or methylphenidate)
Trial: 16740846
Drug: Stimulant (post-trial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stimulant (post-trial management)
Trial: 8204943
Drug: Droloxifene 100
RxNorm normalized name: Droloxifene
DrugBank: Droloxifene (DB15641)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droloxifene 100 mg/day
Trial: 3402181
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of metoclopramide (loading dose of 3 mg/kg followed by 0.5 mg/kg/hr for 12 hours)
Trial: 3402181
Drug: Bolus doses
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus doses of metoclopramide (2 mg/kg added to each bolus dose)
Trial: 3402181
Drug: Continuous infusion
RxNorm normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continuous infusion of metoclopramide (placebo of 5% dextrose injection)
Trial: 3402181
Drug: Bolus doses
RxNorm normalized name: SET,INFUSION,BOLUS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bolus doses of metoclopramide (placebo of 5% dextrose injection)
Trial: 29658353
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (5‐mg intravenous injection, administered 1 week postoperatively)
Trial: 29658353
Drug: Placebo (administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (administered 1 week postoperatively)
Trial: 6837864
Drug: Depilatory cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Depilatory cream
Trial: 18435231
Drug: Oral health
RxNorm normalized name: CETYLPYRIDINIUM CHLORIDE 0.07 g in 100 mL ORAL RINSE [Assured Oral Health Fresh Mint]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral health education by health visitor, including dental health advice, toothbrush and toothpaste with 440 ppm fluoride, provided during home visits at ages 8 months and 20 months.
Trial: 16586358
Drug: Trivalent baculovirus-expressed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trivalent baculovirus-expressed HA vaccine at 45 microg
Trial: 27082828
Drug: Methylphenidate treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylphenidate treatment
Trial: 1330019
Drug: Cholera toxin
RxNorm normalized name: Cholera toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera toxin (15 micrograms or 25 micrograms) administered into a 'closed' jejunal segment
Trial: 1330019
Drug: Cholera toxin
RxNorm normalized name: Cholera toxin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholera toxin administered by mouth with sodium bicarbonate
Trial: 27598679
Drug: Transvenous neurostimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transvenous neurostimulation (treatment group)
Trial: 24247616
Drug: Varespladib (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Varespladib (500 mg daily for 16 weeks)
Trial: 11487536
Drug: Natalizumab (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Natalizumab (3 mg/kg infusion)
Trial: 31994643
Drug: 5% naproxen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5% naproxen patches
Trial: 17897470
Drug: Placebo patches
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo patches